Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion"), headquartered in Vancouver, British Columbia, owns a minority equity interest in Amryt Pharma plc (AIM:AMYT), a biopharmaceutical company based in Dublin, Ireland, focused on rare and orphan diseases. Information related to Novelion’s business, and the risks and uncertainties inherent in an investment in Novelion, can be found in press releases, regulatory filings and other documents appearing on this website. Contact investors@novelion.com for additional information.
Effective October 9, 2019, Novelion’s common stock ceased trading on Nasdaq, and commenced trading on an over-the-counter market under the symbol NVLNF; information on this website regarding Novelion common stock trading prices on Nasdaq are for historic reference only and do not reflect current market value.